Milk Thistle: Benefits, Dosage & Side Effects (2026)

Milk thistle is an extract of the seeds of Silybum marianum, a spiny Mediterranean plant in the daisy (Asteraceae) family used as a liver remedy for two millennia. Its active fraction is silymarin — not a single molecule but a complex of flavonolignans (silibinin, also spelled silybin, plus silychristin and silydianin) together with the flavonoid taxifolin. Silibinin is the most biologically active of these, so a product's real strength depends on two numbers: how much silymarin it contains and how much of that silymarin is silibinin. Quality extracts are standardized to roughly 70-80% silymarin; a raw "milk thistle seed" capsule with no percentage on the label can contain a small and unpredictable fraction of the active compounds.

The second axis — the one most buyers miss — is absorption. Silymarin is poorly water-soluble and poorly absorbed from the gut, so a large share of an ordinary capsule never reaches the bloodstream. This is why the more serious formulations use a phospholipid complex, binding silibinin to phosphatidylcholine (the branded silybin-phosphatidylcholine complex Siliphos / IdB1016) to raise absorption several-fold over plain extract. Milk thistle therefore has the same practical problem as curcumin: standardized silymarin percentage plus a bioavailability-enhanced form are what separate a product that delivers a meaningful dose from a cheap powder that mostly passes through you.

It is also worth separating the supplement from milk thistle's one genuinely strong clinical use. Intravenous silibinin (Legalon SIL) is a recognized hospital antidote for Amanita phalloides ("death cap") mushroom poisoning, where it helps block toxin uptake into liver cells. That is a purified drug given by infusion under medical supervision — not the same thing as an oral capsule for everyday liver health, and its success does not transfer to the supplement's much weaker case for treating chronic liver disease.

On paper, milk thistle's biology is attractive. Silibinin is a direct free-radical scavenger that also raises intracellular glutathione, the liver's main antioxidant defense. It stabilizes the hepatocyte cell membrane, which is thought to reduce uptake of toxins (the mechanism behind the intravenous Amanita antidote), and in preclinical models it damps NF-κB-driven inflammation, inhibits stellate-cell activation (the driver of fibrosis), and stimulates ribosomal RNA polymerase I to support hepatocyte protein synthesis and regeneration. That is a plausible, multi-target hepatoprotective profile — which is exactly why the herb has such a strong reputation.

The problem is that this mechanistic promise has not translated cleanly into hard clinical outcomes. The Cochrane review by Rambaldi and colleagues (PMID 17943794) pooled randomized trials of milk thistle in alcoholic and hepatitis B/C liver disease and found no significant effect on all-cause mortality or liver-related complications; when the analysis was restricted to high-quality, low-bias trials, the apparent benefits disappeared. The earlier Rambaldi 2005 systematic review in the American Journal of Gastroenterology (PMID 16279916) reached the same null conclusion. Most tellingly, the modern NASH RCT by Wah Kheong and colleagues (PMID 28419855) gave non-alcoholic steatohepatitis patients silymarin at 2,100 mg/day and missed its primary histologic endpoint — the reduction in NAFLD activity score was numerically larger than placebo but not statistically significant.

So how should a reader weigh this? The most defensible read is that milk thistle is a low-risk antioxidant support agent with a modest, fairly consistent ability to nudge liver enzymes (ALT/AST) down, but without demonstrated benefit on the outcomes that matter most — mortality, cirrhosis progression, or liver histology. A more favorable narrative review by Gillessen and Schmidt (PMID 32065376) emphasizes enzyme, symptom, and quality-of-life improvements, but a narrative review sits at a lower evidence tier than the Cochrane meta-analysis and does not overturn the null findings on hard endpoints. Milk thistle is best understood as an adjunct, judged on bloodwork over months, not as a treatment that reverses liver disease.